Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design

Area of Science:

• Pharmacogenomics
• Respiratory Medicine
• Molecular Genetics

Background:

• Asthma and COPD are chronic airway diseases with airflow obstruction.
• The beta(2)-adrenoceptor plays a key role in bronchodilation.
• Genetic variations (polymorphisms) in the ADRB2 gene can alter receptor function and potentially impact disease phenotypes and treatment responses.

Purpose of the Study:

• To review the association between beta(2)-adrenoceptor gene (ADRB2) polymorphisms and asthma/COPD.
• To highlight the potential impact of these polymorphisms on disease severity, bronchial hyperresponsiveness, and response to beta-adrenoceptor agonist medications.
• To emphasize the need for optimized study designs in genetic association studies of ADRB2 in airway diseases.

Main Methods:

• Literature review of studies investigating ADRB2 polymorphisms in asthma and COPD.
• Analysis of associations between specific polymorphisms (e.g., Arg16Gly, Gln27Glu) and clinical outcomes.
• Discussion of factors contributing to robust genetic association study design.

Main Results:

• While some studies show no link between ADRB2 polymorphisms and asthma susceptibility, others associate them with asthma severity and bronchial hyperresponsiveness.
• Coding region polymorphisms may influence patient response to common asthma medications (beta-adrenoceptor agonists).

Conclusions:

• Beta(2)-adrenoceptor gene (ADRB2) polymorphisms are relevant to asthma and COPD phenotypes and pharmacogenomics.
• High-quality study design, including appropriate subject selection, outcome measures, and statistical analysis, is essential for advancing our understanding of ADRB2's role in airway diseases.